Tubulis

TubulisTubulis
T

Tubulis

Develops antibody-drug conjugates (ADCs) for targeted cancer therapy.

2013Active118
Rate

About

Tubulis generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties, demonstrating durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Their lead programs, TUB-040 and TUB-030, are being evaluated in the clinic for high-need solid tumor indications. Tubulis aims to expand the therapeutic potential of ADCs for patients, partners, and through their pipeline.

Technology stack

detected 2026-06-30
CDN
Cloudflare
EmailProofpoint
gateway-fronted
Stack
Tailwind CSSBootstrap
Analytics
Google Tag Manager
Hiring
Workday
Languages
Python3JavaScriptRustTypeScript
GPU / CUDA
Triton2
Data platforms
Apache AirflowApache SparkDatabricks
DevOps
DockerGitHub Actions
Cloud
Google Cloud5AWS3Azure
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Tubulis do?

Tubulis generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties, demonstrating durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Their lead programs, TUB-040 and TUB-030, are being evaluated in the clinic for high-need solid tumor indications. Tubulis aims to expand the therapeutic potential of ADCs for patients, partners, and through their pipeline.

How much funding has Tubulis raised?

Tubulis has raised a total of $437M in funding. The most recent round on record is Series C.

Where is Tubulis headquartered?

Tubulis is headquartered in Munich, Germany.

When was Tubulis founded?

Tubulis was founded in 2013.

What industry does Tubulis operate in?

Tubulis operates in BiTech, MedTech, HealthTech, Drug Discovery, Oncology, Antibody-Drug Conjugates.

How many employees does Tubulis have?

Tubulis has approximately 118 people on record.